Quarter













I mean….yeah. The loss of humira was always expected, it’s just the failure to produce a worthy successor. Oral surveillance killed rinvoq and qulipta is a dog. Skyrizi and vraylar are good but will never come close to humira.
 












Buy something so they can destroy it with their antiquated sales model? AbbVie is living in a world of big pharma 1999. The patient is not the “North Star”. This organization is too bloated with too many layers of bureaucracy and an outdated sales model focused on pods, reach & frequency and managing metrics. AbbVIe should get lean and focus on R&D. That would be smarter for the long game. Except no one in this shallow company is in it for the long game and being a real developer of innovation for patients.
 


















Among the smartest things Rick has done is limit R&D investment. This is not a winning team. They need to go buy something. That would be money better spent.
Buy something, build a patent thicket, market the bejeebers out of it. How imaginative. Failure of imagination will doom this company to many years of mediocrity.